Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population

Gastrointestinal Cancer

Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Eur J Cancer

Vo-Quang E, Campani C, Allaire M, Bouattour M, Regnault H, Marra F, Sutter O, Leroy V, Trepo E, Mouri S, Thabut D, Ozenne V, Sidali S, Hollande C, Boros C, Nahon P, Ganne-Carrié N, Lequoy M, Amaddeo G, Nault JC, Paris Liver Cancer Group

doi: 10.1016/j.ejca.2026.116704

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

Gastrointestinal Cancer

Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Eur J Cancer

Lee PC, Cortellini A, Stefanini B, Yoo C, Chon HJ, Cheon J, Kudo M, Nishida N, Scheiner B, Pinter M, Lombardi P, Fulgenzi CAM, D'Alessio A, Brunetti L, Torkpour A, Valenzi E, Crowley F, Marron TU, Hsu WF, Celsa C, Cabibbo G, Cammà C, Galle PR, Vivaldi C, Masi G, Sharma R, Lin RP, Lin CY, Wietharn B, Saeed A, Tovoli F, Piscaglia F, Dalbeni A, Auriemma A, Sacerdoti D, Parisi A, Manfredi GF, Dondo A, Rimassa L, Pirisi M, Schönlein M, von Felden J, Singal AG, Parkih ND, Andanamala H, Ulahannan S, Roehlen N, Thimme R, Huang YH, Pinato DJ

doi: 10.1016/j.ejca.2026.116749

Gastrointestinal Cancer

Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data

Clin Cancer Res

Campani C, Shim JH, Bouattour M, Touchefeu Y, Delhoume V, Rosmorduc O, Pascale A, An J, Lee HC, Regnault H, Thabut D, Amaddeo G, Ningarhari M, Ollivier-Hourmand I, Métivier C, Ronot M, Ntandaja-Wandji L, Ozenne V, Sidali S, Marra F, Hollande C, Ganne-Carrié N, Nahon P, Peron JM, Lequoy M, Sharma R, Liver Cancer Group P, Allaire M, Nault JC

doi: 10.1158/1078-0432.CCR-25-4943

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

SPECIAL REPORT

Gynecologic Cancer

Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer

Gastrointestinal Cancer

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

Eur J Cancer

Antoniotti C, Marmorino F, Rossini D, Schmoll HJ, Lonardi S, Tonini G, Borelli B, Cupini S, Stein A, Moretto R, Bergamo F, Ronzoni M, Germani MM, Zaniboni A, Fazio R, De Grandis MC, Ongaro E, Masi G, Cremolini C

doi: 10.1016/j.ejca.2025.115713

Lung, Respiratory and Thoracic Cancer

Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO

JTO Clin Res Rep

Falchero L, Amrane K, Godbert B, Leterre B, Madelaine J, Fournel P, Mascaux C, Raimbourg J, Schneider S, Swalduz A, Veillon R, Langlais A, Missy P, Morin F, Westeel V, Girard N

doi: 10.1016/j.jtocrr.2026.100964

Gastrointestinal Cancer

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study

ESMO Open

Moik F, Huemer F, Doleschal B, Taghizadeh H, Reimann P, Kostmann SM, Wagner L, Abdel Hamid M, Zimmer KC, Suppé SA, Bachleitner C, Schaberl-Moser R, Amann A, Wolf D, Greil R, Jost PJ, Winder T, Rumpold H, Weiss L, Gerger A, Seeber A, Riedl JM

doi: 10.1016/j.esmoop.2026.106907

Related content

Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO

Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study